Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply

Affiliations

Comment

George W Sledge Jr et al. JAMA Oncol. 2020.

. 2020 Jul 1;6(7):1122-1123.

doi: 10.1001/jamaoncol.2020.1518.

No abstract available

Comment on

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A. Sledge GW Jr, et al. JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782. JAMA Oncol. 2020. PMID: 31563959 Free PMC article. Clinical Trial.
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Gil-Sierra MD, Briceño-Casado MDP, Fénix-Caballero S. Gil-Sierra MD, et al. JAMA Oncol. 2020 Jul 1;6(7):1122. doi: 10.1001/jamaoncol.2020.1516. JAMA Oncol. 2020. PMID: 32463423 No abstract available.
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Sun R, Kim DH, Wei LJ. Sun R, et al. JAMA Oncol. 2020 Jul 1;6(7):1121-1122. doi: 10.1001/jamaoncol.2020.1513. JAMA Oncol. 2020. PMID: 32463424 No abstract available.